VirionHealth Ltd, a Coventry, UK-based biotechnology company developing novel therapeutics for respiratory viral infections, raised up to £13m in Series A funding.
Abingworth made the investment.
The company intends to use the funds to advance its novel programs into the clinic.
Founded in 2017 based on research by Professors Nigel Dimmock and Andrew Easton at the University of Warwick’s School of Life Sciences, VirionHealth develops broad-spectrum therapy, potentially simplifying and accelerating treatment by removing the need for differential diagnosis. Initially focusing on influenza and respiratory syncytial virus (RSV), the company’s technology combats a range of viruses with a single therapeutic agent.
In addition to the funding, Jeffrey Almond, formerly Vice President of Discovery Research and External Research and Development at Sanofi Pasteur, joined the company as Chairman of the Board, which also includes:
– Nicola Thompson, whose previous roles include Vice President and Head of External Drug Discovery at F. Hoffmann-La Roche Ltd, who joins as CEO;
– Laura Lane, COO; Peter Goodfellow, formerly Senior Vice President for Discovery Research at GlaxoSmithKline and an Advisor to Abingworth;
– John Shields, formerly Senior Vice President, Research, at Cantab Pharmaceuticals and an Advisor to Abingworth; and
– Tim Haines, Managing Partner of Abingworth.
FinSMEs
12/10/2017